VRCA verrica.com Earnings per share growth this year

Verrica Pharmaceuticals (VRCA) relies on external contractors for drug manufacturing, making the business dependent on CMO quality. The YoY EPS trend confirms the current state of affairs, where the -30.60 mark reflects the latest data. Sales of YCANTH and new wart therapies are driving growth. The environmental footprint is minimal, as the company is implementing paperless workflows and recyclable applicator packaging.
Analytical breakdowns and data insights for company Verrica (VRCA)

This indicator captures the annual percentage change in net earnings per share. By analyzing the comparable year-over-year growth rate of earnings per share, an investor assesses the efficiency of capital management. The metric is calculated as the difference between current and previous EPS values, revealing the actual increase in profitability. For Verrica Pharmaceuticals (VRCA), this figure reflects the scaling effect of innovative drugs. The high margins of mass-producing dermatological products translate directly into accelerated profit growth.